OncoMatch/Clinical Trials/NCT07652580
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Official title: Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System
Is NCT07652580 recruiting? Yes, currently enrolling (Oct 2026).
The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: induction treatment for NHL
Actively undergoing induction treatment for NHL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Uniformed Services University of the Health Sciences · Bethesda, Maryland
- Walter Reed National Military Medical Center · Bethesda, Maryland
- Naval Medical Center Portsmouth · Portsmouth, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07652580 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior induction treatment for NHL disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages